Categories Uncategorized

City Council of Easthampton Approves Psychedelics Reform Measure

Last week, the city council of Easthampton, Massachusetts, passed a psychedelics initiative that calls for some drugs and entheogenic substances to be decriminalized. The initiative, which was approved in a 7 to 0 vote, had been filed by Owen Zaret, a member of the City Council. The effort was spearheaded by Bay Staters for Natural Medicine (baystatersnm.org), a group of grassroots volunteers that has passed near-identical resolutions in three other Massachusetts cities.

After the vote, Zaret stated in an interview that he felt indebted to the council for being forward thinking, noting that this progress would allow individuals to access effective therapies while also terminating needless arrests and imprisonments. However, the initiative doesn’t require law enforcement to deprioritize the enforcement of rules and laws that prohibit psychedelic substances. This is in addition to being nonbinding.

The measure also states that the possession and use of every controlled substance should first be understood and primarily seen as a public health issue by city commissions, boards, agencies, departments and all other city employees. Legislators recommend that arresting individuals for possessing or using controlled substances intended for personal therapeutic use by adults, excluding the use of animal-sourced controlled substances and lophophora, be the lowest priority of law enforcement in Easthampton.

In a phone interview, Zaret stated that the misuse of substances wasn’t a criminal issue but a public health issue. He explained that an aggressive campaign was needed to call attention to the truth that substance misuse was a matter of public health.

This move by the Easthampton city council comes soon after the city council of Northampton approved a measure stating that no police or government funds shall be utilized in the enforcement of laws that criminalize individuals for possessing or using entheogenic fungi and plants. Easthampton is the fourth city to decriminalize psychedelics, with the other two being the cities of Cambridge and Somerville.

Psychedelic-reform movements are also advancing in other parts of the country, with the city council of Seattle recently passing a measure to decriminalize noncommercialized activities around various psychedelic substances, which include the sharing and growing of nonpeyote-sourced mescaline, ibogaine, ayahuasca and psilocybin mushrooms.

In the state of Michigan, the city council of Grand Rapids passed an initiative in September that also calls for the decriminalization of an extensive range of psychedelic substances. The city council of Ann Arbor has opted to make enforcing laws governing psychedelic substances such as DMT, ayahuasca and psilocybin among the lowest priorities in the city. Soon after this, legislators in the city declared September to be Entheogenic Fungi and Plants Awareness Month.

Different city councils and states are doing what they can to bring about psychedelic policy reform, and so are companies such as Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF). These efforts are likely to change public perception and trigger legal reforms in a growing number of jurisdictions, with the public being the ultimate winner since these substances have been proven to possess medicinal properties.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

4 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

2 months ago